Skip to content
SAMDI Tech
Better. Faster. Label-Free.
  • Why Label-Free Assays
  • Drug Discovery Solutions
    • Overview
    • Assay Development
    • High-Throughput Screening
    • SAMDI Affinity Selection Mass Spectrometry (ASMS) Technology
    • Small Molecule Compound Libraries
    • Cell-Based Assays
    • Substrate Specificity Profiling
    • Beyond Label-Free
      • Optical Assay Solutions
      • Radioactivity Assay Solutions
  • Scientific Resources
  • About Us
    • About Us
    • Executive Leadership
    • Board of Directors
    • Strategic Partnerships
    • Recognition and Awards
    • News
    • Events
    • Careers
  • Contact Us
  • Careers
  • Search

COVID-19

  • Why Label-Free Assays
  • Drug Discovery Solutions
    • Overview
    • Assay Development
    • High-Throughput Screening
    • SAMDI Affinity Selection Mass Spectrometry (ASMS) Technology
    • Small Molecule Compound Libraries
    • Cell-Based Assays
    • Substrate Specificity Profiling
    • Beyond Label-Free
      • Optical Assay Solutions
      • Radioactivity Assay Solutions
  • Scientific Resources
  • About Us
    • About Us
    • Executive Leadership
    • Board of Directors
    • Strategic Partnerships
    • Recognition and Awards
    • News
    • Events
    • Careers
  • Contact Us

Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic. While the development of vaccines…

Webinar: Integrating Affinity Selection Mass Spectrometry (ASMS) Into a Drug Discovery Workflow

Abstract High-throughput screening remains one of the most powerful, unbiased approaches in drug discovery for revealing novel small molecule modulators…

Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the global COVID-19 pandemic. Nonstructural protein 14…

Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development

Abstract The 3-chymotrypsin-like cysteine protease (3CLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered a major target for…

Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic that began in 2019. The…

  • Privacy Policy
  • Contact Us

SAMDI Tech, Inc.
3440 South Dearborn Street
Suite 220S
Chicago, IL 60616

Phone: 312.235.3575

© 2023 SAMDI Tech, Inc. All rights reserved.

Connect with us on
  • Why Label-Free Assays
  • Drug Discovery Solutions
    • Overview
    • Assay Development
    • High-Throughput Screening
    • SAMDI Affinity Selection Mass Spectrometry (ASMS) Technology
    • Small Molecule Compound Libraries
    • Cell-Based Assays
    • Substrate Specificity Profiling
    • Beyond Label-Free
      • Optical Assay Solutions
      • Radioactivity Assay Solutions
  • Scientific Resources
  • About Us
    • About Us
    • Executive Leadership
    • Board of Directors
    • Strategic Partnerships
    • Recognition and Awards
    • News
    • Events
    • Careers
  • Contact Us
  • Careers
  • Search